Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

To harness the cytotoxic capacity of immune cells for the treatment of solid tumors, we developed tetravalent, bispecific tandem diabody (TandAb) antibodies that recognize EGFRvIII, the deletion variant III of the epidermal growth factor receptor (EGFR), and CD3 on T-cells, thereby directing immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellwanger, Kristina, Reusch, Uwe, Fucek, Ivica, Knackmuss, Stefan, Weichel, Michael, Gantke, Thorsten, Molkenthin, Vera, Zhukovsky, Eugene A., Tesar, Michael, Treder, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442391/
https://www.ncbi.nlm.nih.gov/pubmed/28596941
http://dx.doi.org/10.3389/fonc.2017.00100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442391/
https://www.ncbi.nlm.nih.gov/pubmed/28596941
http://dx.doi.org/10.3389/fonc.2017.00100

Ejemplares similares